NCT06888323 2026-03-18Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other TreatmentNational Cancer Institute (NCI)Phase 1 Suspended30 enrolled